A 42-year-old woman from Delhi presents with postmenopausal vaginal bleeding for 3 weeks. On examination, a friable, bleeding cervical mass is noted. Pap smear from 2 years ago was normal. Cervical biopsy shows invasive squamous cell carcinoma. MRI pelvis shows a 4 cm cervical lesion with parametrial involvement but no distant metastases. What is the most appropriate treatment modality?

Explanation

## Management of Locally Advanced Cervical Cancer (LACC) **Key Point:** Concurrent chemoradiation therapy (CCRT) followed by brachytherapy is the gold standard for locally advanced cervical cancer (FIGO stage IB2–IVA) and offers superior survival compared to radiation alone. ### FIGO Staging and This Patient's Stage | FIGO Stage | Description | Size/Extent | |---|---|---| | IB1 | Confined to cervix | ≤4 cm | | **IB2** | **Confined to cervix** | **>4 cm** | | IIA | Beyond cervix, no parametrial involvement | Upper 2/3 vagina | | **IIB** | **Beyond cervix with parametrial involvement** | **Upper 2/3 vagina** | | IIIA | Lower 1/3 vagina involved | | | IIIB | Pelvic sidewall/hydronephrosis | | | IVA | Bladder/rectal mucosa | | | IVB | Distant metastases | | **This patient: 4 cm lesion + parametrial involvement = FIGO Stage IIB (Locally Advanced Cervical Cancer)** ### Treatment Algorithm for Cervical Cancer ```mermaid flowchart TD A[Cervical Cancer Diagnosed]:::outcome --> B{Stage?}:::decision B -->|IA1| C[Cone biopsy or simple hysterectomy]:::action B -->|IA2-IB1| D[Radical hysterectomy + PLND]:::action B -->|IB2-IVA| E[Concurrent Chemoradiation]:::action E --> F[External Beam Radiation]:::action F --> G[Brachytherapy]:::action B -->|IVB| H[Palliative chemotherapy]:::action E --> I[Chemotherapy: Cisplatin weekly]:::action I --> J[Improved OS vs RT alone]:::outcome ``` ### Why CCRT + Brachytherapy for LACC? **High-Yield:** The GOG 120 and RTOG 90-01 trials demonstrated that concurrent cisplatin-based chemotherapy with radiation improves overall survival by 30–35% compared to radiation alone in LACC. **Clinical Pearl:** Cisplatin acts as a radiosensitizer, enhancing tumor cell death. Weekly cisplatin (40 mg/m² IV) during external beam radiation is standard. ### Treatment Sequence 1. **External Beam Radiation Therapy (EBRT):** 45–50 Gy to pelvis over 5–6 weeks 2. **Concurrent Chemotherapy:** Cisplatin 40 mg/m² IV weekly during EBRT 3. **Brachytherapy:** Intracavitary radiation (cesium-137 or high-dose-rate iridium-192) delivering 85–90 Gy to point A over 4–5 insertions ### Why NOT Surgery (Radical Hysterectomy)? - Parametrial involvement (Stage IIB) makes the tumor unresectable with adequate margins - Surgical morbidity is high with parametrial disease - CCRT + brachytherapy offers superior outcomes with acceptable toxicity **Warning:** Do not confuse early-stage disease (IA–IB1) managed by surgery with locally advanced disease (IB2–IVA) managed by chemoradiation.